SCHEMBL24253475

SCHEMBL24253475

CC(C)Cc1ccc2c(c1F)CCN(C)C2

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
HSP90AA1 P07900 2/20 0.35
NMT1 P30419 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HSP90AB1 P08238 1/20 0.33
P2RX7 Q99572 1/20 0.33
KLKB1 P03952 2/20 0.32
ACACB O00763 1/20 0.32
DRD1 P21728 2/20 0.32
DRD5 P21918 2/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253534 0.85 HTR2C (0.42) HTR2CHTR2BMAOAMAOBACACB
SCHEMBL25444509 0.79 MAOA (0.49) HTR2CHTR2BMAOAMAOBKDM4E
SCHEMBL25091105 0.78 HTR2C (0.40) HTR2CHTR2BMAOAMAOBHSP90AA1
SCHEMBL24253339 0.77 MAOA (0.37) HTR2CHTR2BMAOAMAOBHSP90AA1
SCHEMBL22993443 0.74 MAOA (0.46) MAOAMAOBKDM4EDRD1DRD5
SCHEMBL14473194 0.73 ADRA2A (0.46) MAOAMAOBDRD1DRD5DRD2
SCHEMBL24253500 0.72 MAOA (0.45) HTR2CHTR2BMAOAMAOBHSP90AA1
SCHEMBL24688335 0.71 HSP90AA1 (0.35) HTR2CHTR2BMAOAMAOBHSP90AA1
SCHEMBL22993218 0.69 MAOA (0.47) MAOAMAOBNMT1DRD1DRD5
SCHEMBL24253472 0.69 MAOA (0.40) HTR2CHTR2BMAOAMAOBDRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885MAOA 175/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885MAOA 175/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 HTR2C 4421/4885HTR2B 2259/4885MAOA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.